← Back
BioCardia
BCDA · listed on Nasdaq · worth $13.82 million
$0.9131
−0.75% on Nov 4
25 insider buys in the last year, $149.4K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
12.3M shares
81% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders bought BioCardia stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
Simon H. Stertzer
Bought $64.6K on Jun 22 — 70,200 shares at $0.9200, 55% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
President and CEO
Peter Altman
Bought $5.6K on Feb 4 — 5,000 shares at $1.13, 1.8% of what they now own.
0 of 2 earlier purchases did better than the S&P 500
All reports
Every insider trade and SEC report we hold for BioCardia.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
32 more with Pro →Analysts, earnings and news
Analysts' price target
$15.50 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q1 '26−$0.21 a share−$0.04
Q4 '25−$0.06 a share+$0.14
Q3 '25−$0.24 a share+$0.01
Q2 '25−$0.40 a share+$0.10